Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Smith & Nephew Snats ( (SNN) ).
Smith & Nephew disclosed on 24 March 2026 that activist investor Cevian Capital II GP Limited has sharply increased its stake in the company, according to a regulatory filing of major holdings. The move underscores growing shareholder engagement around the medtech group, as strategic investors build positions that could shape future governance and operational decisions.
Cevian crossed a key ownership threshold on 19 March 2026, lifting its voting interest from about 5.0% to 10.09%, equivalent to 85,790,848 indirect voting rights held via nominee Aurora Nominees Limited and custodian UBS AG. The doubling of Cevian’s stake signals a stronger activist presence on the share register, a development investors will watch for potential pressure on performance, portfolio focus or capital allocation at Smith & Nephew.
The most recent analyst rating on (SNN) stock is a Buy with a $41.00 price target. To see the full list of analyst forecasts on Smith & Nephew Snats stock, see the SNN Stock Forecast page.
Spark’s Take on SNN Stock
According to Spark, TipRanks’ AI Analyst, SNN is a Outperform.
The score is driven primarily by improving financial performance (margin and cash flow rebound) and supportive technicals (price above major moving averages with positive momentum). Valuation is only average at a 22.7 P/E, while the earnings call adds confidence via upbeat 2026 growth/profit guidance but flags meaningful near-term tariff and reimbursement headwinds.
To see Spark’s full report on SNN stock, click here.
More about Smith & Nephew Snats
Smith & Nephew plc is a UK-based medical technology company listed in London, best known for orthopaedics, sports medicine and advanced wound management products. The group focuses on supplying surgical devices and related medical technologies to healthcare providers globally, competing in a concentrated medtech market where large institutional shareholders can exert significant influence over strategy.
Average Trading Volume: 886,930
Technical Sentiment Signal: Buy
Current Market Cap: $13.5B
Learn more about SNN stock on TipRanks’ Stock Analysis page.